Pricing Log in Create free account

Immix Biopharma, Inc. (IMMX) vs Kura Oncology, Inc. (KURA)

Immix Biopharma, Inc. and Kura Oncology, Inc. are both Biotechnology companies. Immix Biopharma, Inc. and Kura Oncology, Inc. are of similar size ($604.9M and $596.9M). Immix Biopharma, Inc. has the higher net margin (0.00% vs −384.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Immix Biopharma, Inc. leads on 11 and Kura Oncology, Inc. on 1.

Valuation

Metric IMMX KURA Biotechnology median
P/E n/m n/m 10.60
P/S n/m 8.31 9.40
P/B 2.23 13.25 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 1.71 9.02
Earnings yield (10.97%) (46.68%) (32.88%)
Free cash flow yield (7.64%) (18.30%) (23.13%)

Profitability

Metric IMMX KURA Biotechnology median
Gross margin — 99.35% 68.51%
Operating margin 0.00% (411.90%) 0.00%
Net margin 0.00% (384.30%) 0.00%
Free cash flow margin 0.00% (152.06%) 0.00%
Return on equity (34.18%) (167.71%) (51.96%)
Return on assets (31.34%) (46.73%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMMX KURA Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (17.11%) (57.43%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMMX KURA Biotechnology median
Debt to equity 0.00 0.20 0.00
Current ratio 25.13 4.73 4.97
Net debt to EBITDA 3.39 2.11 1.01

Dividend

Metric IMMX KURA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IMMX KURA Biotechnology median
Market cap 596.90m 604.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack